Tumor progression locus 2 reduces severe allergic airway inflammation by inhibiting Ccl24 production in dendritic cells Allergic asthma is a hyperinflammatory disease of the airways, initiated in atopic individuals by allergen-presenting dendritic cells (DCs) leading to the recruitment of cytokine-secreting T cells and eosinophils to the lungs. [1] [2] [3] Repeated allergen exposure results in local tissue inflammation and remodeling with systemic elevated levels of circulating IgE. 4 Despite a good understanding of the pathogenesis of allergic asthma, the mainstay for treatment continues to be inhaled broad-scale corticosteroids, which have a number of significant side effects. Furthermore, an increasing number of patients are resistant to corticosteroid treatment 5 and there are an increasing number of patients who develop severe asthma. Consequently, there is an urgent medical need to understand in more detail the molecular mechanisms of severe allergic asthma to identify new therapeutic targets. 6, 7 The mitogen activated protein-3 kinase tumor progression locus 2 (TPL-2; also known as mitogen-activated protein kinase kinase kinase 8 [MAP3K8] and cancer Osaka thyroid oncogene [COT] ) phosphorylates and activates MEK1/2 after stimulation of Toll-like receptors (TLRs) and the receptors for TNF and IL-1b, leading to the activation of extracellular-signal regulated kinase (ERK) 1/2 MAP kinases. 8 The TPL-2/ERK1/2 signaling pathway regulates cytokine and chemokine production in inflammatory responses. [9] [10] [11] Studies with TPL-2-deficient Map3k8 2/2 mice have indicated that TPL-2 promotes inflammation in models of endotoxin shock, pancreatitis, liver fibrosis, and thrombocytopenia.
9,12-14 TPL-2 is also required for proficient immunity to intracellular bacterial and protozoan infection. 15, 16 We, and others, demonstrated that TPL-2 signaling in radiation-resistant stromal cells, but not T cells or any other hematopoietic cell, promotes the onset and severity of experimental autoimmune encephalomyelitis, a model of multiple sclerosis. 17, 18 Although these studies highlight the importance of the TPL-2/MEK/ERK signaling axis in type 1 and T H 17 immune responses, the role of TPL-2 in mediating type 2 responses has not been clearly established. A previous study suggested that T-cell-intrinsic TPL-2 regulated CD4
1 T H 2 cell differentiation in vitro via ERK1/2 activation. 19 The authors subsequently hypothesized that increased type 2-associated ovalbumin-induced airway inflammation in TPL-2-deficient mice was due to a Tcell-intrinsic deficiency of TPL-2; however, this was not tested.
In our studies, we found that T-cell receptor (TCR) activation of ERK1/2 in purified CD4 1 T cells was completely independent of TPL-2. 17 These results prompted us to formally test whether Tcell-intrinsic TPL-2 was required for type 2 immunity in vivo using a clinically relevant allergen, house dust mite (HDM), 20 in various models of allergic airway inflammation.
In the present study, we show that TPL-2 deficiency led to severe HDM-induced airway allergy, when compared with wildtype (WT) HDM-treated mice. Using adoptive transfer experiments and cell lineage-specific conditional knockout mice, we show that TPL-2 in T cells and B cells was not required for control of severe airway allergy after HDM challenge. Rather, we found an essential role for TPL-2 in DCs, restraining their promotion of excessive airway inflammation. Using several in vivo models with genomewide RNA sequencing, we identified that TPL-2 regulated the expression and production of Ccl24 (eotaxin-2) by DCs. Furthermore, blocking Ccl24 in vivo abrogated the exacerbated airway inflammation induced by TPL-2-deficient DCs, demonstrating a previously unappreciated role for DC-intrinsic TPL-2 in regulating Ccl24 to limit severe airway allergy.
METHODS
For detailed Methods, see this article's Online Repository at www. jacionline.org.
RESULTS

TPL-2 inhibits HDM-induced airway allergy
Intraperitoneal allergen sensitization followed by localized airway challenge is a well-established CD4
1 T-cell-dependent model of airway allergy. 21 To investigate the role of TPL-2 in airway allergy, we sensitized and challenged WT and Map3k8 2/2 mice with HDM, one of the most common aeroallergens affecting humans 20 (Fig 1, A) . One day after the final intratracheal airway challenge, we observed significantly increased total cellular infiltration in the bronchoalveolar lavage (BAL) fluid of Map3k8 2/2 mice compared with WT mice (Fig 1, B) . We observed no baseline differences between the 2 groups of mice after PBS injection (Fig 1) . Differential cell counts revealed that Map3k8 2/2 mice had significantly increased numbers of eosinophils, macrophages, neutrophils, and lymphocytes in the BAL fluid (Fig 1, B) . In addition, Map3k8 2/2 mice had significantly increased numbers of eosinophils in the lung compared with WT mice (see Fig E1, A, in this article's Online Repository at www.jacionline.org). Accompanying the increased airway inflammation, we also observed augmented perivascular and peribronchial tissue inflammation and a loss of lung architecture in TPL-2-deficient mice (Fig 1, C) . Consistent with the increased pulmonary inflammation, we also observed a significant increase in airway resistance in HDM-challenged Map3k8 2/2 mice upon administration of increasing doses of methacholine compared with HDM-challenged WT mice (Fig 1, D) .
In line with elevated airway and tissue inflammation in Map3k8 2/2 mice, we observed an increased frequency and total number of IL-4-, IL-5-, and IL-13-secreting T H 2 cells, with decreased IFN-g-secreting T cells in the lungs of Map3k8 2/2 mice compared with WT controls (Fig 1, E) . The frequency of IL-5-and IL-13-secreting group 2 innate lymphoid cells was unchanged (Fig E1, B) . Consistent with elevated lung T H 2 cells, Map3k8 2/2 mice had significantly increased mRNA expression for type 2 cytokines Il5 and Il13 in the lung (Fig 1, F) . Although the expression of Ifng was significantly reduced, that of Il4 remained unchanged in Map3k8 2/2 mice compared with WT controls (Fig 1,  F) . In accordance with this, HDM-specific recall responses in the local draining lymph node (LN) cultures revealed increased IL-5 and IL-13 production by Map3k8 2/2 mediastinal lymph node (medLN) cells (Fig 1, G) . Serum levels of IgE were also elevated in Map3k8 2/2 mice compared with WT mice (Fig 1, H) . Activation of the TLR4 signaling pathway contributes significantly to airway allergy after HDM challenge. 22, 23 Given that TPL-2 signals downstream of TLR4, we tested whether the observed increased airway allergy in Map3k8 2/2 mice was restricted to HDM-induced allergy. Sensitization and airway challenge with Der p1, the cysteine protease component of HDM or chicken egg ovalbumin, also invoked significantly increased allergic airway inflammation in Map3k8 2/2 mice, compared with WT mice (Fig E1, C-F) . Together, these data extend the previous report 19 and clearly demonstrate an important regulatory role for TPL-2 in modulating allergic airway responses in several model systems.
Neither T-cell-intrinsic nor B-cell-intrinsic TPL-2 regulates HDM-induced airway allergy
Although it was previously suggested that T-cell-intrinsic TPL-2 was responsible for elevated airway inflammation in TPL-2-deficient mice, this was not directly tested in vivo. 19 We therefore assessed whether TPL-2 function specifically in T cells was responsible for the increased allergic airway responses in complete Map3k8 2/2 mice, using 2 independent and complementary approaches.
First, we established mixed bone marrow (BM) chimeric mice with 80% Tcra 2/2 BM cells mixed with 20% WT or 20% Map3k8 2/2 BM cells transferred to Rag2 2/2 hosts. In the resulting chimeras, all the T cells developed from either WT or TPL-2-deficient donor BM, whereas the majority (80%) of other hematopoietic cells were derived from TPL-2-sufficient Tcra 2/2 BM. Reconstitution of CD4 1 T cells between the 2 chimeric groups was identical (Fig 2, A) . Following HDM sensitization and airway challenge, we observed no differences in the total cellular infiltration or the number of eosinophils in the BAL fluid of chimeric mice with WT T cells or TPL-2-deficient T cells (Fig 2, B) . Similarly, pulmonary inflammation was comparable between the 2 groups of chimeric mice (Fig 2, C) . BM from WT Il4 GFP1 and Map3k8 2/2 Il4 GFP1 mice was used to reconstitute the chimeric mice, allowing us to track T H 2 cells in the chimeric mice by flow cytometry. We performed fluorescence-activated cell sorting analysis on the lung and LN cell populations and observed no significant differences in the frequency and number of CD4 (Fig 2, D) . Furthermore, no differences were detected in the expression of Il4, Il5, and Il13 in the lungs of allergen-challenged chimeric mice (Fig 2, E) . Finally, HDM restimulation of medLN cells from each group of chimeric mice resulted in similar levels of IL-5 and IL-13 secretion (Fig 2, F) .
Second, we used a Cre expression system under the Cd4 promoter to delete TPL-2 in T cells using mice with a LoxP-flanked 
Map3k8
fl/wt mice ( Fig E2, C) . Pulmonary inflammation was also comparable between the genotypes (Fig E2, D) , with no difference in mRNA expression for type 2 cytokines in the lung (Fig E2, E) or the secretion of IL-5 and IL-13 by HDMrestimulated medLN cells (Fig E2, F) . Together, these complementary experiments clearly demonstrated that the enhanced allergic responses to HDM in Map3k8 2/2 mice did not result from the absence of TPL-2 expression in T cells alone. Consistent with this conclusion, TPL-2-deficient T cells were comparable to WT T cells in their ability to differentiate to the T H 2 lineage and produce IL-4 in vitro (Fig E2, G) .
Because various B-cell populations can regulate airway allergy, 24 we next tested the role of B-cell-intrinsic TPL-2, using a similar mixed BM chimeric system with 80% muMT BM mixed with 20% WTor 20% Map3k8 2/2 BM cells transferred to Rag1
hosts. The resulting chimeric mice had similar reconstitution (see Fig E3, A, in this article's Online Repository at www.jacionline. org) and upon HDM sensitization and airway challenge mounted a comparable airway inflammatory response, with similar airway infiltrates ( Fig E3, B) , comparable pulmonary inflammation ( Fig E3, C) , similar expression of ll4 GFP in CD4 1 cells in lung and LN (Fig E3, D) , lung mRNA expression for type 2 cytokines (Fig E3, E) , and HDM-specific cytokine secretion by restimulated medLN cells (Fig E3, F) . Together, these observations indicated that the exacerbated allergic airway inflammation observed in TPL-2-deficient mice was not due to the absence of TPL-2 in the T-cell or B-cell compartments.
TPL-2 function in CD11c
1 DCs regulates HDMinduced airway allergy TPL-2 has well-established signaling functions in innate immune cells, 8, 10 including DCs, which are required for allergen-induced airway inflammation. 25 To test whether TPL-2 in CD11c 1 DCs regulated allergic airway responses, we restricted the deletion of TPL-2 to CD11c 1 cells using Cd11c
Cre Map3k8 fl/ko mice and used the expression of the eYFP reporter to evaluate the efficiency of deletion (Fig 3, A) . Following HDM sensitization and challenge of Cd11c
Cre
Map3k8
fl/ko mice, we observed an increase in the influx of total cells and eosinophils in the BAL fluid, compared with control Cd11c
Cre Map3k8 wt/wt mice; however, this change was not statistically significant (Fig 3, B) . This trend was accompanied by significantly increased inflammation in the lungs, with perivascular and peribronchial cellular infiltration as well as loss of lung architecture (Fig 3, C) . We also detected a significant increase in the frequency and total number of IL-5-and IL-13-secreting T H 2 cells and a trend toward an increase in IL-4-secreting T H 2 cells in the lungs of Cd11c
Cre
Map3k8
fl/ko mice (Fig 3, D) , concurrent with a significant increase in the production of HDM-specific IL-5 and IL-13 in the medLN cell cultures from Cd11c Cre Map3k8 fl/ko mice (Fig 3, E) . As in Map3k8 2/2 mice (Fig 1, H) , we also observed a significant increase in total levels of circulating IgE in Cd11c
Cre Map3k8 fl/ko mice (Fig 3, F) . These results suggest that TPL-2 in CD11c 1 DC negatively regulated airway inflammation after HDM challenge.
It was important to determine whether the enhanced allergic airway responses in Map3k8 2/2 mice were attributable to DCs and not to any other CD11c-expressing cells, such as alveolar macrophages that would delete TPL-2 in Cd11c
Cre Map3k8
fl/ko mice. To do this, we used a LysM Cre driver mouse strain to delete TPL-2 in LysM-expressing cells, including alveolar macrophages. After HDM sensitization and challenge, LysM
Cre-
fl/ko mice mounted a comparable airway inflammatory response to control mice, with similar airway infiltrates (see Fig  E4, A, in this article's Online Repository at www.jacionline. org), comparable pulmonary inflammation ( Fig E4, B) , lung mRNA expression for type 2 cytokines (Fig E4, C) , and HDM-specific cytokine secretion by restimulated medLN cells (Fig E4, D) upon HDM sensitization and airway challenge. These observations indicated that the exacerbated allergic airway inflammation observed in TPL-2-deficient mice was not due to a cell-intrinsic defect of TPL-2 in alveolar macrophages.
To further test whether DC-intrinsic TPL-2 was required to regulate airway inflammation, we used a well-established adoptive transfer system using HDM-pulsed bone marrow-derived dendritic cells (BMDCs).
1 WT and Map3k8 2/2 BMDCs (see Fig E5, A and B, in this article's Online Repository at www.jacionline.org) were pulsed overnight with HDM and then transferred via intratracheal administration into naive WT mice (Fig 4, A) . In line with experiments with Map3k8 2/2 mice and Cd11c
Cre Map3k8 fl/ko mice, mice receiving a single adoptive transfer of Map3k8 2/2 BMDCs followed by 2 intratracheal challenges displayed significantly increased infiltration of total cells, eosinophils, and lymphocytes in the BAL fluid compared with mice given HDM-pulsed WT BMDCs (Fig 4, B) . Mice receiving unpulsed WT and Map3k8
2/2
BMDCs failed to develop any inflammatory response (data not shown). Augmented pulmonary inflammation was also observed in mice given HDM-pulsed Map3k8 2/2 BMDCs compared with WT BMDCs (Fig 4, C) . Adoptive transfer of HDM-pulsed Map3k8 2/2 BMDCs also resulted in higher levels of ll4 and a trend toward an increase in Il5 mRNA in the lung compared with control WT BMDCs (Fig 4, D) . These observations support the hypothesis that DC-intrinsic TPL-2 regulated airway and tissue inflammation after HDM challenge.
TPL-2 regulates the expression of Ccl24 by dendritic cells
Airway allergy induced by an intranasal (i.n.) HDM sensitization and i.n. challenge regimen (Fig 5, A) is strictly DC-dependent, more physiologically relevant, and does not require the use of aluminum hydroxide as an adjuvant. Using this model, we also observed a significant increase in total BAL cells and eosinophils in the BAL fluid of Map3k8 2/2 mice, compared with WT controls (Fig 5, B) . We observed an increase in the frequency of T H 2 cells producing IL-4, IL-5, and IL-13, although this was not statistically significant, and a significant increase in the total number of IL-4-, IL-5-, and IL-13-secreting T H 2 cells in the lungs of Map3k8 2/2 mice compared with WT controls (Fig 5, C) . In addition, Map3k8 2/2 medLN cell cultures produced significantly more IL-5 and a trend toward more IL-13 after HDM restimulation, compared with WT medLN cell cultures (Fig 5, D) . Serum levels of total IgE were also significantly elevated in Map3k8 2/2 mice compared with WT controls (Fig 5, E) . Together, these observations suggest that TPL-2-mediated control of allergic airway responses was independent of the route of antigen administration and independent of any alum adjuvant-associated effects.
To investigate how TPL-2 regulated DC function, we performed fluorescence-activated cell sorting of CD11c
DCs to high purity (;99%) from the local draining medLNs of intranasally sensitized WT and Map3k8 2/2 mice (Fig 5, F) and performed RNA sequencing. Genomewide transcriptional analysis of purified DCs identified a number of characteristic DC-associated genes, which were comparable in both WT and Map3k8 2/2 DCs (Fig E5, H) . 27 To identify transcriptional differences between WT and Map3k8 2/2 DCs, mRNA expression in Map3k8 2/2 DCs was compared to that in WT DCs and statistically significant differences in gene expression were identified using edgeR analysis (Fig 5, G) . Ccl24 (eotaxin-2), which functions as a potent eosinophil and granulocyte chemoattractant in vivo in both atopic and nonatopic patients 28 and in animal models of airway allergy, 29, 30 was approximately 5.7-fold upregulated in Map3k8 2/2 DCs compared with WT DCs (Fig 5, G) . Interestingly, the expression of Ccr3, the receptor for Ccl24, on T cells is regulated by IL-4 and IL-2 31 and has previously been implicated in the preferential recruitment of T H 2 cells. 32 These data raised the possibility that DC TPL-2 regulated the recruitment of both T H 2 cells and eosinophils by regulating the expression of Ccl24.
TPL-2 restricts Ccl24 production to limit severe allergic airway inflammation Following the observation that Map3k8 2/2 DCs had elevated Ccl24 expression, we evaluated the production of Ccl24 protein by Map3k8 2/2 mice after i.n. HDM sensitization and challenge (Fig 6, A) . Ccl24 protein was barely detectable in BAL fluid after i.n. HDM sensitization (D3) in either WT or Map3k8 2/2 mice (Fig 6, B) . However, at days 12 and 14 after i.n. challenge, Ccl24 protein was clearly detected and significantly elevated on day 12 in the BAL fluid of Map3k8 2/2 mice compared with WT mice (Fig 6, B) . Thus, increased Ccl24 in Map3k8
mice correlated with increased allergic responses (Fig 5 and  Fig 6, B) . To determine whether Map3k8 2/2 DCs were responsible for elevated Ccl24 in vivo and contributed to the severe allergic responses, we first evaluated the levels of Ccl24 in the BAL fluid of WT mice given either HDM-pulsed WT or HDM-pulsed Map3k8 2/2 BMDCs (Fig 6, C) . Similar to intact WT and Map3k8 2/2 mice, we detected very low levels of Ccl24 in the BAL fluid at day 3 and day 6 after cell transfer (Fig 6, D) . However, at day 11 after HDM challenge, we observed a significant increase in Ccl24 in mice given Map3k8 2/2 BMDCs compared with mice given WT BMDCs (Fig 6, D) . These results suggested that the absence of TPL-2 in DCs was responsible for increased Ccl24 in the BAL of HDM-challenged Map3k8 2/2 mice, which correlated with severe airway allergy (Fig 4, B-D, and Fig 6, D) .
To test whether elevated Ccl24 in mice receiving Map3k8
2/2
BMDCs was responsible for severe airway inflammation, we adoptively transferred HDM-pulsed WT or Map3k8 2/2 BMDCs into naive WT mice and neutralized Ccl24 using anti-Ccl24 antibodies (Fig 6, E) . As demonstrated above, mice receiving 
Map3k8
2/2 BMDCs and challenged with HDM had significantly higher airway inflammation with increased eosinophilia and lymphocyte recruitment (Fig 6, F) . Ccl24 blockade had minimal effect on airway inflammation in mice given WT BMDCs; however, Ccl24 blockade completely prevented severe airway inflammation observed in mice given Map3k8
2/2
BMDCs, compared with the isotype-treated control mice (Fig 6, F) . Specifically, blocking Ccl24 reduced airway eosinophilia and lymphocyte recruitment in the BAL fluid of mice given Map3k8 2/2 BMDCs, compared with isotype-treated mice (Fig 6, F) . The increased pulmonary inflammation observed in mice given HDM-pulsed Map3k8 2/2 BMDCs was also significantly reduced upon neutralization of Ccl24, compared with isotype-treated mice (Fig 6, G) . In addition, allergic mice transplanted with Map3k8 2/2 BMDCs had a significant increase in IL-5 and IL-13 production from restimulated HDM-specific medLN cultures compared with mice receiving WT BMDCs (Fig 6, H) . This increased type 2 cytokine production in mice receiving Map3k8 2/2 BMDCs was significantly reduced upon neutralization of Ccl24 compared with isotype-treated control mice (Fig 6, H) . Surprisingly, neutralization of Ccl24 also led to a significant decrease in IL-5 and IL-13 production in mice given WT BMDCs compared with mice treated with isotype control (Fig 6, H) . There was no significant difference between the type 2 cytokine production in mice given WT or Map3k8 2/2 BMDCs along with Ccl24-neutralizing antibody (Fig 6, H) . These observations demonstrated that severe airway allergy with elevated airway eosinophilia, lymphocyte infiltration, and lung inflammation in mice receiving Map3k8 2/2 BMDCs was mediated by Ccl24. Furthermore, Ccl24 regulated HDM-specific type 2 cytokine production from LN cultures, suggesting that Ccl24 also regulated local lymphocyte recruitment. Collectively, these data identify a critical role for DC-intrinsic TPL-2 in preventing severe airway allergic responses to HDM by regulating Ccl24 expression.
DISCUSSION
In the present study, we identified that TPL-2 prevented severe airway allergic responses to HDM, mediated principally by a DCintrinsic function of TPL-2. RNA sequencing of draining medLN DCs identified that TPL-2 critically regulated Ccl24.
Elevated Ccl24 protein was also observed in the BAL fluid of Map3k8 2/2 mice after HDM challenge, suggesting that Ccl24 contributed to the severe airway disease in Map3k8 2/2 mice. Consistent with this hypothesis, severe airway allergy induced by adoptive transfer of Map3k8 2/2 DCs could be blocked by neutralization of Ccl24. Together, these results indicate that DC-intrinsic TPL-2 limits severe airway allergic responses by regulating the production of Ccl24.
The role of TPL-2 in regulating type-1 and T H 17 inflammatory responses has been extensively investigated. 9, 10, 16, 17 In contrast, only a single study has reported a role for TPL-2 in type 2 responses. 19 In agreement with Watford et al, 19 our study confirmed that TPL-2 inhibits type 2 responses. However, the present study, using a more physiologically relevant allergen (HDM) and in several models of airway allergy, clearly demonstrated that TPL-2 expression in T cells was not important in airway allergic responses. This contrasts with the conclusions of this earlier study in which in vitro experiments suggested that a T-cell-intrinsic role for TPL-2 was required to limit type 2 responses. 19 Our results clearly demonstrated that TPL-2 was not required for T H 2 differentiation in vitro and by restricting the deficiency of TPL-2 to T cells, using mixed BM chimeras or T-cell conditional knockout mice, it was evident that T-cell-intrinsic TPL-2 had no role in regulating type 2 responses in vivo.
A critical role of DCs in initiating and activating allergic type 2 responses has previously been demonstrated. 26, 33 However, the molecular mechanisms by which DCs initiate type 2 response are incompletely understood. We did not observe any appreciable differences in the frequency or total number of different DC subsets (CD11b 1 cDCs, CD103 1 DCs, CD64
1 /FcεRIa 1 inflammatory DCs, PDCA1
1 plasmacytoid DCs) between WT and Map3k8 2/2 mice at baseline or after HDM sensitization and challenge either in the lung or in medLNs, suggesting that TPL-2 did not regulate the development or recruitment of different DC subsets ( Fig E5, E and F) . However, we demonstrated that TPL-2 was an important regulator of DC-derived Ccl24, limiting the development of severe airway allergic responses to HDM. On the basis of experiments with Cd11c
Cre Map3k8 fl/ko mice, LysM Cre Map3k8 fl/fl mice, and adoptive transfer experiments with BMDCs and using an intranasal sensitization and challenge system, we established that DC-intrinsic TPL-2 provided an important regulatory role to prevent the development of severe airway allergy. Strikingly, a single adoptive transfer of HDM-pulsed Map3k8 2/2 DCs recapitulated many of the features of severe airway allergy, including increased airway and tissue inflammation, similar to HDMchallenged Map3k8 2/2 mice. Although the array of model systems used in this study converged upon a dominant DC-intrinsic role for TPL-2 in regulating airway and tissue inflammation, several differences also emerged between the model systems. These may be due to additional roles for TPL-2 in other cellular compartments, different routes of sensitization, frequency of airway challenges, and time of analysis. Furthermore, within the DC-specific systems, the role of different DC subsets and different CD11c-expressing cells may also contribute to different aspects of the allergic response. Additional comparative studies using both human and murine DC subsets from allergic and nonallergic individuals are needed to delineate the role of TPL-2 in regulating DC function.
To identify how DC-intrinsic TPL-2 regulated airway allergic responses, we compared the transcriptome of ex vivo CD11c 1 / MHC-II 1 DCs from WT and Map3k8 2/2 mice using a wellestablished model of DC-dependent HDM-mediated airway allergy. 22 Increased allergic responses in Map3k8 2/2 mice using this i.n. model indicated that TPL-2 inhibited airway allergic responses independent of the intraperitoneal priming or the potential impact of the aluminum hydroxide adjuvant. Previous studies have described a range of DC-expressed molecules, including CD40, CD80/86, and OX40, required to activate T H 2 immunity. [34] [35] [36] [37] We did not observe differential expression of any of these molecules between Map3k8 2/2 and WT DCs (Fig  E5, B and G) . Our earlier work also established that TPL-2 regulates the expression of Il12 p35, Il12 p40, Il10, and Ifnb in TLR-activated DC. 10 However, we did not observe differential regulation of any of these cytokines in in vitro HDM-pulsed Map3k8 2/2 DCs (Fig E5, C) . TPL-2 has been previously shown to regulate IFN-g and type 1 responses. 15, 16 However, following HDM-induced airway responses, we did not observe any significant difference in lung Ifng, between the allergic conditional knockout mice in the CD11cCre model (Fig E5, D) , indicating that type 1 responses were intact in mice with TPL-2-deficient DCs. This was in contrast to the observation that allergic Map3k8 2/2 mice had significantly reduced expression of Ifng, compared with allergic WT mice (Fig 1, E) , suggesting CD11c 1 cell independent control of Ifng expression in Map3k8 2/2 mice following HDM sensitization and challenge. These differences suggest that DC-intrinsic TPL-2 regulates HDM-driven type 2 responses in a context-dependent manner, compared with type 1/TLR-mediated responses.
Ccl24 (eotaxin-2) is a chemoattractant for CCR3-expressing cells, predominantly eosinophils and T H 2 lymphocytes, 32, 38 and may contribute to airway remodeling. 39 Hallmark features of type 2 human allergic asthma are circulating, airway, and tissue eosinophils accompanied by elevated T H 2 lymphocytes, suggesting a mechanistic link between elevated DC expression of Ccl24, observed in this study, and elevated airway eosinophilia and type 2 immune responses. Although elevated Ccl24 has been observed in IL-4-treated, type 2-promoting BMDCs and ex vivo DCs from allergic mice, 33, 40 the functional relevance of DC-derived Ccl24 was not investigated in these studies. Murine studies presented here identified that Map3k8 2/2 DCs were sufficient to invoke elevated levels of Ccl24 in the airways of mice following adoptive transfer, concomitant with increased eosinophilia and lymphocyte recruitment, highlighting the importance of Ccl24 in driving a severe allergic response.
The expression of CCR3 on T H 2 cells 32 provides a potential mechanistic explanation for how DC-derived Ccl24 could promote T H 2-driven responses. Consistent with this, neutralizing Ccl24 dramatically reduced airway eosinophilia, lymphocyte infiltration, and lung inflammation in allergic mice given Map3k8 2/2 BMDCs, highlighting a key role of Ccl24 in mediating severe airway allergy in Map3k8 2/2 mice. It will be important to determine whether TPL-2 also regulates CCL24 in human DCs and whether the TPL-2 pathway is compromised in those with severe asthma. In support of this, sputum from patients with severe, treatment-refractory asthma had elevated levels of Ccl24, compared with the sputum of those with nonsevere asthma. 41 Similarly, elevated expression of tissue Ccl24 has been observed in those with severe asthma, correlating with sputum eosinophilia, lower FEV 1 , and more asthma exacerbations. 42 In addition, polymorphisms in the CCL24 gene have been associated with the development of asthma. 43 These data support the notion that elevated Ccl24 may contribute to severe airway allergy and maybe a useful biomarker to identify patients with severe asthma 44 and supports the hypothesis that dysregulated TPL-2 in DCs may contribute to elevated Ccl24 in those with severe asthma; however, this needs to be tested.
Although we demonstrated that Ccl24 was an important mediator of severe allergic responses in mice, it was interesting to note that blockade of Ccl24 had little effect on the allergic airway responses in mice given WT BMDCs, most likely due to the lower levels of Ccl24 observed in the BAL fluid of mice given HDM-pulsed WT DCs or i.n. HDM (Fig 6) . These data suggest that dysregulated Ccl24 may be responsible for the transition from moderate to severe asthma in mice and that other mediators, such as Ccl11 (eotaxin-1) and IL-5, may contribute to airway inflammation in moderate asthma that developed in WT mice. In support of this observation, Ccl24-deficient mice are capable of mounting low levels of airway eosinophilia after ovalbumin challenge. 30 It is also possible that IL-5, Ccl11, and Ccl24 synergistically contribute to severe airway inflammation. Indeed, the coexpression of Ccl11 and Ccl24, 45 or IL-5 and Ccl24, 46 correlates with persistent airway eosinophilia in mice with severe airway allergy.
In conclusion, we have demonstrated that TPL-2 negatively regulates type 2 responses to HDM, preventing the development of severe airway allergic responses. Cell-intrinsic functions in T cells and B cells in airway allergic responses were ruled out, whereas TPL-2 expression in DCs was shown to be essential to regulate the expression of Ccl24 in the lungs after HDM challenge. Antibody-blocking experiments confirmed the importance of elevated Ccl24 in driving severe airway inflammation in Map3k8 2/2 mice. Further study is required to determine whether TPL-2 regulates chemokine secretion, including Ccl24, in human cells and whether alterations in TPL-2 expression/signaling contribute to severe asthma. TPL-2 is widely considered as a promising anti-inflammatory drug target. 47 However, the results in the present study suggest that TPL-2 inhibitors could have unwanted impacts on allergic comorbidities.
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METHODS Animals
HDM-induced airway inflammation
As indicated, mice were sensitized twice via the intraperitoneal route with 100 mg (dry weight) of HDM (Dermatophagoides pternoyssinus extracts, Greer, Lenoir, NC), ovalbumin (10 mg, Sigma, St Louis, Mo), or Der p1 (10 mg; Greer) with Imject Alum (Thermoscientific, Waltham, Mass) diluted in PBS (1:3) solution. After sensitization, mice were challenged twice with 100 mg of HDM, Der p1, or ovalbumin, as indicated, and diluted intratracheally in PBS on days 21 and 24. All the parameters for airway allergy were measured 1 day after the last challenge.
Intranasal sensitization and challenge model
Mice were sensitized intranasally with 100 mg of HDM diluted in PBS and subsequently challenged intranasally with 10 mg of HDM over a period of 5 days from day 7 to day 11. All the parameters for airway allergy were measured 3 days after the last challenge.
BMDC culture and adoptive transfer
BM cells were cultured in the presence of 20 ng/mL GM-CSF (Peprotech, London, United Kingdom) for 10 days. For HDM pulsing, BMDCs were washed and cultured overnight with HDM (10 mg) and 5 ng/mL GM-CSF. The adoptive transfer model has been previously described. E2 Briefly, mature DCs were cultured overnight with 10 mg of HDM, washed with PBS, and transferred intratracheally into naive WT mice. After the initial transfer, mice were challenged with 100 mg of HDM diluted intratracheally in PBS on days 7 and 10. All the parameters for airway allergy were measured 1 day after the last challenge. Blocking antibodies diluted in PBS (Ccl24 antibodies [CCL24/eotaxin-2 MAb (Clone 106521, R&D Systems-Biotechne, Minneapolis, Minn) and CCL24/eotaxin-2 Affinity Purified Polyclonal Ab, R&D Systems-Biotechne]) were mixed and used at 0.03 mg/dose (monoclonal) and 0.006 mg/dose (polyclonal). Isotype controls rat IgG 2A (Clone 54447, R&D systems-Biotechne) and normal goat IgG (R&D systems-Biotechne) were mixed and used in similar ratios. 
Chimeric mice
Airway resistance measurements
Baseline and methacholine-induced airway hyperreactivity measurements of conscious, restrained mice were obtained using a Buxco FinePointe System for noninvasive airway measurement (Buxco Research Systems, Wilmington, NC) according to the manufacturer's instructions. Mice were exposed to aerosolised methacholine (Sigma), administered from 3 to 50 mg/mL for a 5-minute period (30 seconds dosing, 2 minutes recording, and 2.5 minutes recovery), with airway resistance measurements made during the 2 minutes of recording.
BAL fluid preparation and differential cell counts
One day after the last HDM challenge, mice were culled and BAL fluid collected using 1.5 mL of PBS for each mouse. BAL fluid was centrifuged at 300g for 10 minutes at 48C and cells resuspended in equal volumes of complete Iscove's modified Dulbecco's medium (IMDM) (Sigma) (with 10% FCS, 1% 100 U/mL penicillin and 100 mg/mL streptomycin [Gibco, Waltham, Mass], 8 mM L-glutamine [Gibco], and 0.05 mM 2-mercaptoethanol [Gibco]). The BAL fluid was stored at 2808C before analysis. The total number of BAL cells was counted and differential cell counts performed on cytospin preparations stained with Giemsa stain, modified (Sigma).
Histology and inflammation scoring
Excised lungs were fixed in 10% neutral buffered formalin overnight and washed in 75% ethanol. The tissues were embedded in paraffin, and lung sections were stained with hematoxylin and eosin stain. Stained slides were scanned with a VS120-SL slide scanner (Olympus, Tokyo, Japan) and images were analyzed with the OlyVIA image viewer (Olympus). Inflammation scoring was performed as previously described.
E3
Isolation of lung and medLN cells
Mice were culled, bled, and lungs and medLNs collected. Lungs were homogenized and lymphocytes enriched by density gradient centrifugation using 40% Percoll (GE Healthcare, Little Chalfont, United Kingdom). Homogenized medLN cells were cultured at a density of 200,000 cells/well in 200 mL in 96-well round-bottom plates (Sigma) for 4 days, with 10 mg/mL HDM.
Isolation of DCs
For the isolation of ex vivo DCs, medLNs from HDM-sensitized mice were homogenized and separated on a density gradient. To do this, cells were resuspended in a 15% w/v solution of OptiPrep (Sigma) and overlayed with the diluent solution (0.88% w/v sodium chloride, 1 mM ethylene-diamine-tetraacetic acid, 0.5% w/v BSA, 10 mM Hepes-NaOH, pH 7.4) and IMDM. Samples were centrifuged at 600g for 15 minutes at room temperature and the enriched DC layer was collected from the top of the gradient for downstream analysis.
Cell sorting and flow cytometry (GL3), and Ter119 (TER-119). Lineage panel for the group 2 innate lymphoid cell staining was defined as CD4 1 /CD8 . They were cultured for 6 days in vitro with 10 ng/mL IL-4 (R&D Systems-Biotechne, Minneapolis, Minn), 5 ng/mL IL-2 (R&D), 10 mg/mL anti-IFN-g (XMG1.2, BioXcell, West Lebanon, NH), and CD3 (0.1-4.0 mg) (145-2C11, BioXcell) and CD28 (10 mg/mL) (37.51, BioXcell) in IMDM with 10% FCS (and other components as listed above). 
RT-PCR
